pharma · Invasive Extraintestinal Pathogenic Escherichia coli Disease · HIV-1 Infection
Zhejiang Xianju Pharmaceutical
Xian-Janssen Pharmaceutical
Xian-Janssen Pharmaceutical is a pharma organization headquartered in 西安, CN. Primary therapeutic focus areas include Invasive Extraintestinal Pathogenic Escherichia coli Disease, HIV-1 Infection. NovaPharmaNews links 2
西安, CN HQ
146 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 西安, CN
- Employees
- 146
- Programs
- 2
- Drugs
- 5
- Patents
- 0
RILPIVIRINE , JNJ-16150108
Phase 2 · small molecule · HIV-1 Infection
RILPIVIRINE , JNJ-16150108 for HIV-1 Infection is a Phase 2 program (small_molecule) at Xian-Janssen Pharmaceutical with 1 ClinicalTrials.gov record(s).
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Xian-Janssen Pharmaceutical
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- HIV-1 Infection
- Status
- active
- Trials
- 1